Home Press Releases Sickle Cell Disease Treatment Market Size Worth $6.94 Billion By 2030 | CAGR: 18.8%

Sickle Cell Disease Treatment Market Size Worth $6.94 Billion By 2030 | CAGR: 18.8%

The global sickle cell disease treatment market size is expected to reach USD 6.94 billion by 2030, according to a new study by Polaris Market Research. The report “Sickle Cell Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant); By End-Use; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The significant number of unmet medical needs, a healthy pipeline, and a growing patient pool are all expected to boost market growth. As a result of the lack of a complete cure and the risks associated with bone marrow transplantation, there has been an increase in demand for cost-effective drugs and gene therapy for sickle cell disease (SCD) in recent years

.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/sickle-cell-disease-treatment-market/request-for-sample

 

Gene therapy has appeared as the ultimate solution for several critical ailments. In the case of genetic disorders, gene therapy represents a revolution that addresses the disease’s underlying cause. Companies are moving their R&D attention to genetic therapy to fix the genetic mutation in SCD.

 

Moreover, in May 2020, CRISPER Therapeutics and Vertex Pharmaceuticals are also undertaking clinical studies for CTX001, a CRISPR-Cas9 gene-edited treatment. They confirmed that the FDA had granted CTX001, an interventional, patient-derived, gene-edited stem cell-derived hematopoietic therapy, Regenerative Medicine Advanced Therapy (RMAT) distinction for the treatment of serious sickle cell disorder, and transfusion-dependent beta-thalassemia (TDT).

 

Positive clinical tests on CTX001 indicate that the pipeline candidate has the potential to become a blockbuster medicine when it is released. This is projected to drive significant expansion in the SCD therapy industry. Furthermore, the government is funding research and development (R&D) operations designed to motivate researchers and pharmaceutical businesses to create novel medicines.  

 

Sickle Cell Disease Treatment Market Report Highlights

  • Bone Marrow Transplant (BMT) segment is anticipated to grow at a significant CAGR over the forecast period. Only bone marrow transplantation (BMT) can cure SCD. As a result, the preference for BMT is growing throughout North America and Europe. However, the procedure’s high cost and difficulties in locating a matched donor restrict the segment’s growth.
  • Pharmacotherapy segment accounted for a significant revenue share. The government’s significant support for pharmaceutical businesses can be ascribed to the segment’s rapid expansion. Because there are currently few therapy choices on the market, the government encourages research through financing and classifications like orphan pharmaceuticals, fast track, issues that will affect, and others.
  • Asia Pacific is expected to grow at a lucrative CAGR over the projected period. Because of a rising patient population and increasing disposable income levels in this region. Furthermore, the expansion of the healthcare system and increasing government efforts would accelerate the market’s growth in this region.
  • The global players with a global presence include AstraZeneca, Acceleron Pharma, Inc., Arena Pharmaceuticals, Emmaus Life Sciences, Blood Therapeutics, Novartis, Pfizer Incorporation, and Sangamo Therapeutics.

 

Polaris Market Research has segmented the sickle cell disease treatment market report based on treatment, end-use, and region:

 

Sickle Cell Disease Treatment, Treatment Outlook (Revenue – USD Billion, 2018 – 2030)

  • Blood Transfusion
  • Pharmacotherapy
    • Hydroxyurea
    • Branded Drugs
      • Endari
      • Adakveo
      • Oxbryta
      • Zynteglo
      • CTX001
      • Mitapivat
      • FT-4202
    • Bone Marrow Transplant

Sickle Cell Disease Treatment, End-Use Outlook (Revenue – USD Billion, 2018 – 2030)

  • Hospitals
  • Specialty Clinics
  • Others

Sickle Cell Disease Treatment, Regional Outlook (Revenue – USD Billion, 2018 – 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

License and Pricing

Buy Now

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing

Request For Customization

Please specify your research requirement and get customized report


Regional AnalysisSegmentation AnalysisIndustry OutlookCompetitive Analysis
By using this form you agree with the storage and handling of your data by this website.

Speak to Analyst

By using this form you agree with the storage and handling of your data by this website.